Hims & Hers Health, INC Form 4 insider transactions

Oluyemi Okupe, CFO of Hims & Hers Health, exercised stock options and sold shares of Class A Common Stock on March 4, 2024, according to a Form 4 filing with the SEC.

Irene Becklund, PAO of Hims & Hers Health, executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on March 1, 2024, according to a Form 4 filing with the SEC.

Director and Chief Medical Officer Patrick Harrison Carroll sold 20,000 shares of Hims & Hers Health, Inc. and acquired 77,433 restricted stock units.

Oluyemi Okupe, CFO of Hims & Hers Health, reports the acquisition of 367,809 Restricted Stock Units (RSUs) tied to Class A Common Stock.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc., reports the acquisition of 418,141 Restricted Stock Units (RSUs) on February 28, 2024, according to a Form 4 filing with the SEC.

Michael Chi, Chief Marketing Officer of Hims & Hers Health, Inc., reports the sale of 47,687 shares of Class A Common Stock at $13.19 per share and the grant of 309,734 Restricted Stock Units (RSUs).

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., acquired 193,584 Restricted Stock Units (RSUs) on February 28, 2024, according to a Form 4 filing with the SEC.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on February 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director David B. Wells sold 260,000 shares of Hims & Hers Health, Inc. at an average price of $13.1585 on February 28, 2024.

Irene Becklund, PAO of Hims & Hers Health, sold 2,747 shares of Class A Common Stock at $12.08 per share on February 27, 2024, under a pre-arranged 10b5-1 trading plan.